<DOC>
	<DOCNO>NCT02512380</DOCNO>
	<brief_summary>gastric cancer highly aggressive malignancy poor overall outcome . The purpose study evaluate 5-year survival neoadjuvant S1 , oxaliplatin , docetaxel ( SLOT ) versus S1 , oxaliplatin ( SOX ) patient locally advance , resectable gastric/esophagogastric junction ( EGJ ) cancer .</brief_summary>
	<brief_title>Neoadjuvant SLOT Versus SOX Patients With Locally Advanced , Resectable Gastric/Esophagogastric Junction ( EGJ ) Cancer</brief_title>
	<detailed_description>Two arm , phase 3 study neoadjuvant S1 , oxaliplatin , docetaxel ( SLOT ) versus S1 , oxaliplatin ( SOX ) patient locally advance , resectable gastric/esophagogastric junction ( EGJ ) cancer . 380 Patients enrolled trial . The primary objective study determine 5-year survival two arm .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven gastric GE junction adenocarcinoma ; Age : 18 70 ; ECOG 02 ; Adenocarcinoma stomach GE junction accord stag classification TNM Scannographic : T34 N0/N + M0 ; Completion baseline quality life questionnaire Adequate bone marrow function ( ANC ≥ 1,500/ul , blood platelet ≥ 100,000/ul , haemoglobin ≥ 10g/dl ) ; Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) liver function ( serum bilirubin ≤ 1.5UNL , AST/ALT ≤ 3 time ( normal value ) Written inform consent Previous chemotherapy ; Active infection require antibiotic Pregnant , lactate woman Psychiatric illness , epileptic disorder Concurrent systemic illness appropriate chemotherapy History malignancy within 5 year except nonmelanoma skin cancer , cervix situ carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>